CA3089527A1 - Autotaxin inhibitors and uses thereof - Google Patents
Autotaxin inhibitors and uses thereof Download PDFInfo
- Publication number
- CA3089527A1 CA3089527A1 CA3089527A CA3089527A CA3089527A1 CA 3089527 A1 CA3089527 A1 CA 3089527A1 CA 3089527 A CA3089527 A CA 3089527A CA 3089527 A CA3089527 A CA 3089527A CA 3089527 A1 CA3089527 A1 CA 3089527A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- heterocycloalkyl
- solvate
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677459P | 2018-05-29 | 2018-05-29 | |
| US62/677,459 | 2018-05-29 | ||
| US201862731003P | 2018-09-13 | 2018-09-13 | |
| US62/731,003 | 2018-09-13 | ||
| PCT/CN2019/089025 WO2019228403A1 (en) | 2018-05-29 | 2019-05-29 | Autotaxin inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3089527A1 true CA3089527A1 (en) | 2019-12-05 |
Family
ID=68697812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3089527A Pending CA3089527A1 (en) | 2018-05-29 | 2019-05-29 | Autotaxin inhibitors and uses thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10711000B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3728257A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021526123A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111801328B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3089527A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019228403A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019220064A1 (en) * | 2018-02-14 | 2020-10-01 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | Heterocyclic compound, application thereof and pharmaceutical composition comprising same |
| WO2019228403A1 (en) | 2018-05-29 | 2019-12-05 | Fronthera U.S. Pharmaceuticals Llc | Autotaxin inhibitors and uses thereof |
| CN111393459B (zh) * | 2020-04-16 | 2022-07-22 | 南京安纳康生物科技有限公司 | Shp2抑制剂及其用途 |
| JP2023533294A (ja) * | 2020-07-09 | 2023-08-02 | スージョウ アーク バイオファーマシューティカル カンパニー リミテッド | Atx阻害剤及びその製造方法並びに使用 |
| CN113912600A (zh) * | 2020-07-09 | 2022-01-11 | 苏州爱科百发生物医药技术有限公司 | 一种atx抑制剂及其制备方法和应用 |
| WO2022026922A2 (en) * | 2020-07-31 | 2022-02-03 | Genentech, Inc. | Methods for treating exacerbations of inflammatory respiratory diseases |
| CN114315825A (zh) * | 2020-09-30 | 2022-04-12 | 江西济民可信集团有限公司 | 吡啶并咪唑衍生物及其制备方法和应用 |
| WO2022074459A2 (en) * | 2020-10-06 | 2022-04-14 | Ildong Pharmaceutical Co., Ltd. | Autotaxin inhibitor compounds |
| EP4242208A4 (en) * | 2020-11-04 | 2025-01-15 | Xizang Haisco Pharmaceutical Co., Ltd. | DEUTERATED DERIVATIVE USED AS ATX INHIBITOR, AND ITS APPLICATION |
| CN112675308B (zh) * | 2020-12-09 | 2023-05-05 | 中国人民解放军军事科学院军事医学研究院 | 抑制enpp2基因和/或蛋白表达的物质在制备治疗多发性骨髓瘤的药物中的应用 |
| FI4274572T3 (fi) | 2021-01-05 | 2026-03-27 | Zydus Lifesciences Ltd | Uusia autotaksiinin inhibiittoreita |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| TW202342138A (zh) * | 2022-03-31 | 2023-11-01 | 大陸商蘇州愛科百發生物醫藥技術有限公司 | Atx抑制劑或其鹽的結晶形式及其制備方法與應用 |
| WO2023211684A2 (en) * | 2022-04-29 | 2023-11-02 | Noetix Pharma Llc | Prevention and treatment of post-operative cognitive dysfunction (pocd) |
| WO2023247670A1 (en) * | 2022-06-24 | 2023-12-28 | F. Hoffmann-La Roche Ag | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139882A1 (en) * | 2013-03-14 | 2014-09-18 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CN105339370B (zh) * | 2013-06-19 | 2017-09-15 | 加拉帕戈斯股份有限公司 | 用于治疗炎症性疾病的化合物和及其药物组合物 |
| TW201908293A (zh) * | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
| AU2019220064A1 (en) * | 2018-02-14 | 2020-10-01 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | Heterocyclic compound, application thereof and pharmaceutical composition comprising same |
| JP7274767B2 (ja) | 2018-05-24 | 2023-05-17 | ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 | 芳香族複素環式化合物及びその医薬組成物 |
| WO2019228403A1 (en) | 2018-05-29 | 2019-12-05 | Fronthera U.S. Pharmaceuticals Llc | Autotaxin inhibitors and uses thereof |
-
2019
- 2019-05-29 WO PCT/CN2019/089025 patent/WO2019228403A1/en not_active Ceased
- 2019-05-29 CN CN201980015925.4A patent/CN111801328B/zh active Active
- 2019-05-29 JP JP2020540731A patent/JP2021526123A/ja active Pending
- 2019-05-29 EP EP19810155.2A patent/EP3728257A4/en not_active Withdrawn
- 2019-05-29 CA CA3089527A patent/CA3089527A1/en active Pending
- 2019-07-11 US US16/509,300 patent/US10711000B2/en not_active Expired - Fee Related
-
2020
- 2020-05-15 US US16/875,675 patent/US11040972B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3728257A4 (en) | 2021-06-23 |
| US10711000B2 (en) | 2020-07-14 |
| US20190367515A1 (en) | 2019-12-05 |
| CN111801328B (zh) | 2023-06-02 |
| EP3728257A1 (en) | 2020-10-28 |
| JP2021526123A (ja) | 2021-09-30 |
| WO2019228403A1 (en) | 2019-12-05 |
| US11040972B2 (en) | 2021-06-22 |
| CN111801328A (zh) | 2020-10-20 |
| US20200354357A1 (en) | 2020-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11040972B2 (en) | Autotaxin inhibitors and uses thereof | |
| US12390463B2 (en) | Dosage forms and regimens for amino acid compounds | |
| KR102787602B1 (ko) | 아미노산 화합물 및 사용 방법 | |
| US11014881B2 (en) | Hepatitis B capsid assembly modulators | |
| ES2865374T3 (es) | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas | |
| CA3207392A1 (en) | Cdk inhibitor | |
| JP2026506002A (ja) | Sos1阻害剤及び抗がん薬を含む、がんの処置のための医薬組成物 | |
| AU2017258187A1 (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| MX2010010619A (es) | Moduladores de quimioquina. | |
| AU2021268889A1 (en) | Treatment of respiratory diseases with amino acid compounds | |
| JPWO2021132422A1 (ja) | ピリダジニルチアアゾールカルボキシアミド化合物 | |
| BRPI0808707A2 (pt) | Uso de derivados de benzimidazol e composição compreendendo os mesmos | |
| CN105473581A (zh) | 作为溴结构域抑制剂的新取代的双环化合物 | |
| KR20180110132A (ko) | 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제 | |
| TW202329973A (zh) | 整合素抑制劑及其與其他藥劑併用之用途 | |
| AU2022319753A1 (en) | Pyrrolo[2,3-b]pyridine pgdh inhibitors and methods of making and using | |
| CA3166597A1 (en) | Muscarinic receptor 4 antagonists and methods of use | |
| RU2775505C2 (ru) | Изохинолин-3-иловые карбоксамиды и их получение и применение | |
| BR112018072169B1 (pt) | Compostos isoquinolin-3-il carboxamidas, composição farmacêutica compreendendo os ditos compostos e uso terapêutico dos mesmos | |
| HK40005209A (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| HK40005209B (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220719 |